ASCO-GI 2021: Quality of Life Maintained With Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
There were trends toward improvement in quality of life in some domains
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.